• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lab Automation Market is Projected To Reach US$8.71 Billion By 2031 at CAGR of 6.3% | The Insight Partners

    9/22/25 11:30:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email

    NEW YORK, Sept. 22, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global lab automation market is observing significant growth due to technological advancements, regulatory & quality compliance, and demand for efficiency & throughput.

    (PRNewsfoto/The Insight Partners)

    The report runs an in-depth analysis of market trends, key players, and future opportunities. The lab automation market generally comprises a vast array of types, equipment, applications, end users, and geography, which are expected to register strength in the coming years.

    Check valuable insights in the Lab Automation Market report. You can easily get a sample PDF of the report - https://www.theinsightpartners.com/sample/TIPHE100001249/

    Overview of Report Findings

    1.      Market Dynamics and Insights: Laboratories are under pressure to improve operational efficiency while remaining agile in the face of evolving scientific needs, shifting research priorities, and budgetary constraints. Traditional automation systems, which were rigid and monolithic, limited labs' ability to adapt quickly or expand capabilities incrementally.

    In contrast, the new generation of modular automation platforms offers a flexible, building-block approach, allowing laboratories to start small and scale up as demand increases or workflows evolve. This shift reduces the initial capital expenditure and lowers integration complexity, making automation more accessible to facilities, including mid-sized labs, academic research centers, and clinical testing environments.

    By integrating seamlessly with legacy infrastructure and advanced digital tools, these systems enable labs to future-proof their operations and improve return on investment over time. Integrated and scalable systems are central to transforming labs into smart, connected environments. These platforms work cohesively with LIMS, ELNs, and data analytics software, enabling end-to-end automation and real-time decision-making. With increasing emphasis on personalized medicine, high-throughput screening, and data-intensive workflows, labs must be equipped to handle complex processes efficiently and with minimal downtime.

    Modular automation allows for rapid configuration changes, supports parallel workflows, and simplifies maintenance, ensuring operational continuity during upgrades or reconfigurations. The demand for integrated, scalable automation systems is projected to rise, driven by laboratories' pursuit of flexibility, digitalization, and long-term operational resilience. Vendors prioritizing modularity, interoperability, and ease of integration will be best positioned to lead in this evolving market landscape.

    2.      Regional Insights: The Middle East & Africa presents a unique lab automation landscape characterized by extreme diversity in infrastructure, economic conditions, and healthcare priorities. In the Middle East, wealthy Gulf Cooperation Council (GCC) countries such as Saudi Arabia, UAE, Qatar, and Kuwait are investing in smart healthcare infrastructure as part of long-term strategic visions such as Saudi Vision 2030 and Dubai Health Strategy 2021. These countries integrate advanced lab automation, AI, and digital platforms to improve healthcare delivery, attract medical tourism, and support research excellence.

    Institutions such as Cleveland Clinic Abu Dhabi, King Faisal Specialist Hospital, and Pure Health have adopted high-throughput automation solutions from Roche, Siemens, Thermo Fisher, and BD, often tailored to local needs with multilingual interfaces and regional service support. In Africa, South Africa stands out as the most advanced market, with national reference labs under NHLS and private chains such as PathCare deploying automation for infectious disease testing, routine diagnostics, and research.

    Kenya, Nigeria, Egypt, and Ghana focus on affordable, modular automation systems, often delivered through partnerships with NGOs, global health organizations, or aid agencies. Technologies such as Cepheid's GeneXpert are effective in decentralized, disease-specific testing programs. Challenges in the MEA include limited technical training, fragmented logistics, regulatory inconsistencies, and a need for more local service capabilities. However, with increasing government healthcare investment, international collaborations, and the growth of digital health ecosystems, MEA holds significant untapped potential for lab automation expansion.

    3.      Geographical Insights: North America is expected to dominate the lab automation market with the highest market share in 2024.

    Market Segmentation

    •         The lab automation market is bifurcated based on type into equipment and software.

    •         Per equipment, the lab automation market is divided into automated workstations, liquid handling systems, robotic systems, microplate readers, automated storage and retrieval systems (ASRS), and others.

    •         The lab automation market is segmented by application into clinical diagnostics, drug discovery, proteomics solutions, and genomics solutions.

    •         Based on end user, the market is categorized into hospitals, diagnostic centers, pharmaceutical companies, contract research organizations (CROS), and educational and research institutions.

    •         The lab automation market is segmented into five major regions: North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America.

     

    Get Research Sample Copy of the Lab Automation Market: https://www.theinsightpartners.com/sample/TIPHE100001249 

    Competitive Strategy and Development

    • Key Players: A few major companies operating in the lab automation market include Thermo Fisher Scientific Inc.; Siemens AG; Danaher Corp; Honeywell International Inc; Agilent Technologies Inc; Revvity Inc; Analytik Jena GmbH+Co. KG; Abbott Laboratories; Eppendorf SE; and bioMerieux SA.
    • Trending Topics: AI-Driven Workflow Optimization, Modular & Scalable Automation Systems, Integration of Robotics & Smart Lab Equipment, Cloud-Based Data Management, and Lab-as-a-Service (LaaS) Models, among others.

    Global Headlines on the Lab Automation Market

    •         "Revvity, Inc. (NYSE:RVTY) announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient lab workflows. When the accuracy of the T-SPOT TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients benefit from the resultant powerful solution."

    •         "Thermo Fisher Scientific Inc. launched the Thermo Scientific iCAP MX Series ICP-MS to simplify trace element analysis with inductively coupled plasma mass spectrometry (ICP-MS). The launch includes a new single quadrupole Thermo Scientific iCAP MSX ICP-MS and triple quadrupole Thermo Scientific iCAP MTX ICP-MS designed for environmental, food, industrial and research labs to analyze routine and challenging trace elements to detect and mitigate harmful substances."

    Get Premium Copy of Lab Automation Market Size and Growth Report by 2031 at:  https://www.theinsightpartners.com/buy/TIPHE100001249

    Conclusion

    Lab Automation involves the use of advanced technologies, such as robotics, software, and integrated systems, to streamline and enhance laboratory workflows in areas including sample handling, diagnostics, drug discovery, and data analysis. It enables laboratories to increase throughput, improve accuracy, reduce human error, and optimize operational efficiency. Key drivers of growth in the lab automation market include the rising demand for high-throughput testing, increasing adoption of AI and machine learning, growing need for reproducibility in research, and the pressure to reduce operational costs in healthcare and pharmaceutical sectors.

    The report from The Insight Partners provides several stakeholders, including lab equipment manufacturers, software vendors, research organizations, healthcare providers, and regulatory bodies, with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities.

    Trending Related Reports:

    •         Lab Automation in Protein Engineering Market Size, Trends, Shares, and Forecast – 2031

    •         Lab Automation In Genomics Market Size, Trends, Shares, and Forecast – 2031

    •         Lab Automation in Drug Discovery Market Size, Share, Scope 2031

    •         Lab Automation in Clinical Diagnostics Market Size, Share 2031

    •         Total Lab Automation Market Scope 2031

    About Us:

    The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

    Contact Us:

    If you have any queries about this report or if you would like further information, please get in touch with us:

    Contact Person: Ankit Mathur

    E-mail: [email protected]

    Phone: +1-646-491-9876

    Also Available in : Korean | German | Japanese | French | Arabic | Chinese | Italian | Spanish

    Logo: https://mma.prnewswire.com/media/1586348/5449703/The_Insight_Partners_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lab-automation-market-is-projected-to-reach-us8-71-billion-by-2031-at-cagr-of-6-3--the-insight-partners-302563120.html

    SOURCE The Insight Partners

    Get the next $RVTY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    12/15/2025$110.00Buy → Neutral
    BofA Securities
    12/9/2025$105.00Neutral
    Goldman
    10/16/2025Neutral
    Guggenheim
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    More analyst ratings

    $RVTY
    SEC Filings

    View All

    Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVVITY, INC. (0000031791) (Filer)

    2/2/26 7:05:11 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - REVVITY, INC. (0000031791) (Filer)

    1/13/26 9:14:58 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Revvity Inc.

    10-Q - REVVITY, INC. (0000031791) (Filer)

    11/4/25 4:08:31 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

    New launches in high-content imaging, detection, and automation help labs accelerate drug discovery workflows from sample to insight Revvity, Inc. (NYSE:RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation. At booth #612, Revvity will showcase an expanded

    2/5/26 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

    Fourth quarter revenue of $772 million; 6% revenue growth; 4% organic growth Fourth quarter GAAP EPS of $0.87; Adjusted EPS from continuing operations of $1.70 Initiates full year 2026 guidance Revvity, Inc. (NYSE:RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same period a year ago.

    2/2/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening,

    1/26/26 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Revvity downgraded by BofA Securities with a new price target

    BofA Securities downgraded Revvity from Buy to Neutral and set a new price target of $110.00

    12/15/25 9:57:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Revvity with a new price target

    Goldman initiated coverage of Revvity with a rating of Neutral and set a new price target of $105.00

    12/9/25 8:53:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Revvity

    Guggenheim initiated coverage of Revvity with a rating of Neutral

    10/16/25 8:27:52 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Vohra Tajinder S covered exercise/tax liability with 359 shares and was granted 4,448 shares, increasing direct ownership by 39% to 14,531 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/6/26 4:05:08 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Singh Prahlad R. covered exercise/tax liability with 3,421 shares, was granted 26,796 shares, exercised 25,525 shares at a strike of $92.09 and sold $2,557,859 worth of shares (25,525 units at $100.21), increasing direct ownership by 24% to 120,213 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/6/26 4:05:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Goldberg Joel S covered exercise/tax liability with 869 shares, was granted 6,427 shares, exercised 12,717 shares at a strike of $92.09 and sold $1,274,357 worth of shares (12,717 units at $100.21), increasing direct ownership by 15% to 43,247 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/6/26 4:05:06 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

    Fourth quarter revenue of $772 million; 6% revenue growth; 4% organic growth Fourth quarter GAAP EPS of $0.87; Adjusted EPS from continuing operations of $1.70 Initiates full year 2026 guidance Revvity, Inc. (NYSE:RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same period a year ago.

    2/2/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening,

    1/26/26 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

    Revvity, Inc. (NYSE:RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. Update on Financial Performance The Company is also providing the following preliminary financial results for the fourth quarter 2025: Reported and organic revenue growth for the fourth

    1/12/26 4:15:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials